RBC says uniQure Huntington’s data shows ‘signal worth pursuing’

After uniQure shared updated Huntington’s data at the 24-month mark from the ongoing U.S. and European Phase 1/2 clinical trials of AMT-130, RBC Capital analyst Luca Issi, pointed out that the data has “multiple limitations,” including single-arm, a post-hoc analysis and a number of patients that is small. Whether this data is sufficient for accelerated approval remains to be determined and in the firm’s view is “probably still a long shot,” but the firm thinks “this is a signal worth pursuing,” says the analyst, who would be buyers into strength. RBC has an Outperform rating and $16 price target on uniQure shares.